Erythropoietin Drugs Market Size & Share, by Product Type (Biosimilars, First-generation formulation, and Second-generation formulation); Drug Class; Application; and Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Growth Drivers

• Therapeutic use in neurodegenerative conditions: The global prevalence of neurodegenerative diseases like Alzheimer’s and Parkinson’s disease is rising rapidly. Alzheimer's disease is the most common type of dementia, accounting for 50-70% of cases and affecting about 50 million people worldwide. The World Health Organization estimates that 5 to 8% of adults over the age of 60 have dementia, with Alzheimer's disease being the most common type. Currently, it is anticipated that 6.5 million U.S. residents aged 65 and older suffer from Alzheimer's disease; by 2060, this figure is expected to rise to 13.8 million.
  
  Studies have shown that EPO can cross the blood-brain barrier and may reduce inflammation, oxidative stress, and cell apoptosis, factors contributing to cognitive decline. This has led researchers to explore EPO’s role in managing neurodegenerative conditions and improving the quality of life for patients.
• Advancements in drug development: Innovations in formulations, biosimilars, and drug delivery systems expanding treatment options and accessibility are driving the erythropoietin drugs market. New formulations that offer extended or sustained release are improving patient convenience and adherence. Long-acting EPO formulations reduce the need for frequent dosing, which is particularly beneficial for patients with chronic conditions requiring ongoing anemia treatment. Long-acting variants such as darbepoetin alfa and epoetin beta pegol allow for once-weekly or even once-monthly administration, as opposed to multiple doses per week with older formulations.
  
  Moreover, researchers are developing next-generation EPO analogs and derivatives designed to enhance the effectiveness of treatment and reduce side effects. These drugs aim to be more selective and may exhibit a reduced risk of complications, such as blood clots, that have been associated with some EPO treatments. This also encourages adoption among a wider range of patients, including those with heightened sensitivity or comorbid conditions.
• Rising awareness and improved diagnostics: Rising awareness and improved diagnostic capabilities are significantly driving the erythropoietin drugs market, as they enable earlier detection and more precise treatment of anemia-related conditions. Modern diagnostic tools such as automated complete blood count (CBC) analyzers and more sensitive biochemical markers, are enabling earlier and more accurate anemia diagnosis.
  
  Several key players are innovating and launching advanced CBC analyzers that support early and accurate diagnosis of anemia, indirectly driving demand for EPO drugs. For instance, Sysmex is a global leader in hematology diagnostics, offering a range of CBC analyzers, including the Sysmex XN-Series and XE-Series. These analyzers provide high accuracy and advanced diagnostic features, such as the ability to detect abnormal cells and reticulocyte counts, which are useful for anemia diagnosis.

Challenges

• High treatment costs: EPO drugs can be costly, especially branded versions, making them less accessible in low and middle-income regions. Although biosimilars have improved affordability, price remains a barrier in many countries with limited healthcare funding, affecting EPO adoption rates.
• Side effects and safety concerns: EPO drugs can cause adverse effects, such as hypertension, blood clots, stroke, and in some cases, increased tumor progression in cancer patients. These safety risks have led to regulatory restrictions on EPO use, especially for off-label applications, limiting its erythropoietin drugs market potential.